Recent Updates
Recently added Catalysts

BMN 190

Phase 1

Jansky-Bielschowsky Disease | Monoclonal antibody | Other |BioMarin Pharmaceutical Inc.|Last Updated: Aug 24, 2022

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLEDDMCBiomarker
Total Trials2
Total Enrollment47
FDA Designations
No designations recorded
Clinical Trials (2)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT02485899An Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 190 in Patients With CLN2 DiseasePHASE1 COMPLETED 23Feb 1, 2015Dec 10, 2020Aug 24, 20224 United States, Germany +2
NCT01907087A Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Intracerebroventricular BMN 190 in Patients With Late-Infantile Neuronal Ceroid Lipofuscinosis (CLN2) DiseasePHASE1 COMPLETED 24Sep 1, 2013Nov 1, 2015Mar 8, 20195 United States, Germany +2
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Probability of Unreversed 2-point Decline in Motor-language (ML) Score or Score of 0
Up to Week 289

Motor and Language are each 0-3 point subscales in which 3 represents best function and 0 represents loss of function. Thus, the 0-6 point ML score was used as the primary mode of evaluation of loss of function. In 190-201, the primary endpoint was a responder endpoint: unreversed ML 2-point decline or score of 0 at Week 48 compared to the 50% rate expected in natural history using the 1-sample binomial test. For 190-202, the primary endpoint was revised to assess response over the full duration of follow-up. It is not clear, given the variable follow-up much greater than 48 weeks, what response rate is expected in natural history. For this reason, the assessment of the primary endpoint is based on comparing to natural history data and using the Kaplan-Meier method and Cox proportional hazards model with covariate adjustment (i.e., baseline ML score and age as continuous covariates, and genotype \[common alleles\] and sex as categorical covariates).

Probability of Unreversed Motor-language (ML) Score of Zero.
Up to Week 289

Motor and Language are each 0-3 point subscales in which 3 represents best function and 0 represents loss of function. Thus, the 0-6 point ML score was used as the primary mode of evaluation of loss of function. In 190-201, the primary endpoint was a responder endpoint: unreversed ML 2-point decline or score of 0 at Week 48 compared to the 50% rate expected in natural history using the 1-sample binomial test. For 190-202, the primary endpoint was revised to assess response over the full duration of follow-up. It is not clear, given the variable follow-up much greater than 48 weeks, what response rate is expected in natural history. For this reason, the assessment of the primary endpoint is based on comparing to natural history data and using the Kaplan-Meier method and Cox proportional hazards model with covariate adjustment (baseline ML score, age, genotype \[common alleles\], and sex).

Motor-Language (ML) Scale Score During 300 mg Dosing Period
Baseline, Week 49/Last Assessment

The progression of ceroid lipofuscinosis (CLN2) disease was assessed using adapted motor and language domains of the Hamburg rating scale (ML scale score). Motor and Language are each 0 - 3 point subscales in which 3 represents best function and 0 represents loss of function. The sum of the motor and language scores (ML score, 0-6 points) was used to evaluate the loss of function.

Secondary Endpoints
Whole Brain Volume
Baseline (Week 1 of BMN 190-201) to Week 289 / Last observation
Volume of Cerebrospinal Fluid
Baseline (Week 1 of BMN 190-201) to Week 289 / Last observation
Volume of Total Cortical Gray Matter
Baseline (Week 1 of BMN 190-201) to Week 289 / Last observation
Unlock Study Endpoints
Study Design & Arms
AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
BMN190 recombinant human tripeptidyl peptidase-1 (rhTPP1)EXPERIMENTALAll 190-202 study subjects administered BMN 190 300 mg by continuous Intracerebroventricular (ICV) infusion at a rate of 2.5 mL/hour for approximately 4 hours) every 14 days.
BMN190EXPERIMENTALrecombinant human tripeptidyl peptidase-1 (rhTPP1/cerliponase alfa)
Interventions
NameTypeDescription
BMN 190BIOLOGICAL300 mg Intracerebroventricular (ICV) infusion administered every other week for up to 240 weeks
Intracerebroventricular (ICV) access deviceDEVICESurgical implantation of an MRI compatible ICV access device in the lateral ventricle of the right hemisphere is required for administration of study drug.
Unlock Study Design Details
Eligibility Criteria
Age Range3 Years — 16 Years
SexALL
Healthy VolunteersNo
Study Sites4

Inclusion Criteria: * Must have completed 48 weeks in Study 190-201. * Is willing and able to provide written, signed informed consent. Or, in the case of patients under the age of 18 (or other age as defined by regional law or regulation), provide written assent (if required) and have written info...

Countries:United StatesGermanyItalyUnited Kingdom
Unlock Eligibility Criteria